Ergebnis der Suchanfrage nach celle
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
- 2
LAMILUX SUNSATION® wins German Innovation Award
Ein Dokumentmehr - 3
PR: LAMILUX Composites innovations at transport logistic
Ein Dokumentmehr DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehrTechnische Universität München
Genetically encoded nano-barcodes
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Electron microscopy: Nano-reporter proteins make invisible processes visible Genetically encoded nano-barcodes - New gene reporter system for electron microscopy - Uses barcodes to identify cellular states and structures that would otherwise remain unidentified - Important step to better elucidate cellular structural changes also in disease How do the nerve cells in our brain communicate with each other? What processes take place ...
mehr- 4
The rise of Carbon Dioxide (CO₂) as a renewable carbon feedstock – More than 1.3 million tonnes capacity for CO₂-based products already exist and are expected to at least quadruple by 2030
Ein Dokumentmehr Project TwinTrace: Customcells works together with partners on a smart battery factory
mehr- 3
Sysmex Europe Launches the UF-1500 Fully Automated Urine Particle Analyser
mehr Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
Ein DokumentmehrLAMILUX Composites at the transport logistic in Munich
Ein Dokumentmehr- 2
Press Release - One year of digital print folders: hubergroup Print Solutions takes stock
Ein Dokumentmehr - 3
Press Release: SGL Carbon expands material portfolio with new carbon fiber for high-strength pressure vessels
Ein Dokumentmehr DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrMiltenyi Biotec acquires biosensor company lino Biotech
Zurich (ots) - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy ...
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehrDeutsche Telekom revolutionizes eSIM transfer with Google
mehrCustomcells strengthens sustainable battery industry ‘Made in Germany’
mehrEBiSC presents a new offering of iPSC-derived neurons
mehrMagenta heartbeat: What Deutsche Telekom is showing at MWC 2023
mehrMWC: Deutsche Telekom and European Space Agency strive for maximum resilience
Bonn / Barcelona, February 27th, 2023 MEDIAINFORMATION Deutsche Telekom and European Space Agency strive for maximum resilience - Joint initiative for more secure networks with borderless connectivity - Memorandum of understanding signed to improve integration of satellites - DT achieves worldwide first 5G-connection from stratosphere backhauled over Intelsat's ...
mehrPR: LAMILUX Composites :The strongest and lightest tank cladding
Ein DokumentmehrEES EUROPE: Storage Systems for a resilient Energy Supply
mehrSwiss Start-Up “Mirai Foods” produces first cultivated tender steak / Breakthrough for Cultivated Premium Beef Steaks
Zurich (ots) - - Three patents for key technologies in “cultivated meat” - Food producer Angst AG takes stake in company - Innovative bioreactor improves efficiency and reduces costs A real new meat experience without sacrifice: Swiss start-up Mirai Foods achieves technological breakthrough for the cultivation ...
mehrBreakthrough - EUR 50 million investment for start-up BrainRepair UG / Pivotal trial on stem cell treatment for brain damage in newborns fully funded
mehrPR: LAMILUX at CV Show Birmingham 2023, Hall 5 Stand B03
Ein DokumentmehrCO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg
Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...
mehrThe smarter E Europe 2023: START-UPS AND YOUNG COMPANIES TO THE NEW ENERGY WORLD TAKE CENTER STAGE
Munich/Pforzheim (ots) - The smarter E Europe 2023, Europe’s largest platform for the energy industry, offers a comprehensive overview of the latest developments and trends in the areas of renewable energies, decentralization and digitalization of the energy industry and presents cross-sector solutions from the ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
mehr